Singulex, Inc. Announces Two Studies Utilizing Company’s Proprietary System For Cardiovascular Risk Assessment At American Heart Association Scientific Sessions
11/13/2013 10:19:45 AM
Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced two studies using the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI) will be presented at the American Heart Association Scientific Sessions in Dallas, Texas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by